ClearPoint Neuro (CLPT)
(Delayed Data from NSDQ)
$5.33 USD
+0.07 (1.33%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $5.34 +0.01 (0.19%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$5.33 USD
+0.07 (1.33%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $5.34 +0.01 (0.19%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum B VGM
Zacks News
Why ClearPoint Neuro (CLPT) Stock Might be a Great Pick
by Zacks Equity Research
ClearPoint Neuro (CLPT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
ClearPoint Neuro, Inc. (CLPT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
ClearPoint Neuro, Inc. (CLPT) delivered earnings and revenue surprises of 13.64% and 6.41%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
ClearPoint's (CLPT) Prism System Favored by Latest Study
by Zacks Equity Research
ClearPoint's (CLPT) Prism Neuro Laser Therapy System is likely to provide an integrated solution for precise and more efficient laser interstitial thermal therapy.
OrthoPediatrics (KIDS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
OrthoPediatrics (KIDS) delivered earnings and revenue surprises of 17.86% and 0.06%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Integra LifeSciences (IART) Misses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Integra (IART) delivered earnings and revenue surprises of -1.11% and 0.44%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Inogen (INGN) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Inogen (INGN) delivered earnings and revenue surprises of -75.38% and 2.81%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
ClearPoint Neuro (CLPT) Gets FDA's Nod for New Software
by Zacks Equity Research
ClearPoint Neuro's (CLPT) receipt of the FDA's latest approval is likely to provide fast, peri-procedural segmentation of the cortical structures of the brain.
Shockwave Medical (SWAV) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Shockwave Medical (SWAV) delivered earnings and revenue surprises of 26.09% and 1.47%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
ClearPoint's (CLPT) Neuro Systems to Boost Neurosurgeries
by Zacks Equity Research
ClearPoint (CLPT) is likely to provide effective neurosurgical operations with the installation of the ClearPoint Prism Neuro Laser Therapy System and the Neuro Navigation System.
Silk Road Medical (SILK) Stock Jumps 12.7%: Will It Continue to Soar?
by Zacks Equity Research
Silk Road Medical (SILK) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
ClearPoint Neuro (CLPT) Gets FDA's Nod for SmartFrame OR System
by Zacks Equity Research
ClearPoint Neuro's (CLPT) receipt of the FDA's latest approval is likely to serve a wider patient pool than its legacy portfolio.
How Much Upside is Left in ClearPoint Neuro, Inc. (CLPT)? Wall Street Analysts Think 48.77%
by Zacks Equity Research
The mean of analysts' price targets for ClearPoint Neuro, Inc. (CLPT) points to a 48.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
ClearPoint Neuro, Inc. (CLPT) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
ClearPoint Neuro, Inc. (CLPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength Seen in OrthoPediatrics (KIDS): Can Its 8.1% Jump Turn into More Strength?
by Zacks Equity Research
OrthoPediatrics (KIDS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
ClearPoint Neuro, Inc. (CLPT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
ClearPoint Neuro, Inc. (CLPT) delivered earnings and revenue surprises of -61.11% and 0.85%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Inogen (INGN) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Inogen (INGN) delivered earnings and revenue surprises of 34.38% and 10.33%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
ClearPoint Neuro, Inc. (CLPT) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
ClearPoint Neuro, Inc. (CLPT) delivered earnings and revenue surprises of 21.05% and 6.61%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Shockwave Medical (SWAV) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Shockwave Medical (SWAV) delivered earnings and revenue surprises of 35.29% and 4.36%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
ClearPoint Neuro, Inc. (CLPT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
ClearPoint Neuro, Inc. (CLPT) delivered earnings and revenue surprises of 0% and 0.70%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Hologic (HOLX) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Hologic (HOLX) delivered earnings and revenue surprises of 37.68% and 11.88%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Is Acadia Healthcare (ACHC) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Acadia Healthcare (ACHC) and ClearPoint Neuro, Inc. (CLPT) have performed compared to their sector so far this year.
ClearPoint Neuro, Inc. (CLPT) Surges 7.6%: Is This an Indication of Further Gains?
by Zacks Equity Research
ClearPoint Neuro, Inc. (CLPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
ClearPoint Neuro, Inc. (CLPT) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
ClearPoint Neuro, Inc. (CLPT) delivered earnings and revenue surprises of -21.43% and -1.64%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
ClearPoint Neuro, Inc. (CLPT) Stock Jumps 9.8%: Will It Continue to Soar?
by Zacks Equity Research
ClearPoint Neuro, Inc. (CLPT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Earnings Preview: ClearPoint Neuro, Inc. (CLPT) Q1 Earnings Expected to Decline
by Zacks Equity Research
ClearPoint Neuro, Inc. (CLPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.